ProMPT Renewal
Lead Research Organisation:
University of Cambridge
Department Name: Oncology
Abstract
Prostate cancer is the commonest solid tumour in men. We deperately need biomarkers that predict how in the future an individual cancer is likely to behave. The development of a clinically linked repository across the two prostate cancer collaboratives is critical in achieving this, and will underpin the science that is funded through more conventional routes.
Technical Summary
The two prostate cancer collaboratives are moving towards the provision of infrastructure only for the remaining two years of the funding. We are concentrating on developing a clinically linked bio-bank for prostate cancer for tissue, nucleic acids, and paraffin embedded tissue, as well as liquid based collections.
Organisations
- University of Cambridge, United Kingdom (Lead Research Organisation)
- University of Oxford, United Kingdom (Collaboration)
- CARIS Life Sciences (Collaboration)
- Memorial Sloan Kettering Cancer Center (Collaboration)
- Karolinska Institute, Sweden (Collaboration)
- University of Bristol, United Kingdom (Collaboration)
- Imperial College London, United Kingdom (Collaboration)
- Karolinska University Hospital (Collaboration)
- GlaxoSmithKline (GSK) (Collaboration)
- Institute of Cancer Research UK (Collaboration)
- Dana-Farber Cancer Institute (Collaboration)
- University of Toronto (Collaboration)
- AstraZeneca plc (Collaboration)
- Biosignatures Ltd (Collaboration)
- deCODE Genetics (Collaboration)
- Royal Marsden NHS Foundation Trust (Collaboration)
Publications
Adamson RE
(2012)
In vitro primary cell culture as a physiologically relevant method for preclinical testing of human oncolytic adenovirus.
in Human gene therapy
Ahmad I
(2011)
Ras mutation cooperates with ß-catenin activation to drive bladder tumourigenesis.
in Cell death & disease
Ahmad I
(2011)
HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer.
in Proceedings of the National Academy of Sciences of the United States of America
Ahmad I
(2011)
K-Ras and ß-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder.
in Disease models & mechanisms
Ahmad I
(2011)
ß-Catenin activation synergizes with PTEN loss to cause bladder cancer formation.
in Oncogene
Al Olama AA
(2014)
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.
in Nature genetics
Al-Lamki RS
(2010)
Tumor necrosis factor receptor expression and signaling in renal cell carcinoma.
in The American journal of pathology
Altay G
(2011)
Differential C3NET reveals disease networks of direct physical interactions.
in BMC bioinformatics
Amin Al Olama A
(2013)
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.
in Human molecular genetics
Anandadas CN
(2011)
Early prostate cancer--which treatment do men prefer and why?
in BJU international
Ankerst DP
(2012)
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
in World journal of urology
Armstrong K
(2011)
Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer.
in British journal of cancer
Arsov C
(2013)
Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial.
in European urology
Avery KN
(2013)
Behavior theory for dietary interventions for cancer prevention: a systematic review of utilization and effectiveness in creating behavior change.
in Cancer causes & control : CCC
Avery KN
(2013)
Understanding surgical interventions in RCTs: the need for better methodology.
in Lancet (London, England)
Avery KN
(2013)
Men with prostate cancer make positive dietary changes following diagnosis and treatment.
in Cancer causes & control : CCC
Baker MJ
(2010)
An investigation of the RWPE prostate derived family of cell lines using FTIR spectroscopy.
in The Analyst
Barbiere JM
(2012)
The association of diagnosis in the private or NHS sector on prostate cancer stage and treatment.
in Journal of public health (Oxford, England)
Barrett T
(2012)
DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study.
in Magnetic resonance in medicine
Bennett HL
(2010)
Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells.
in Cell death & disease
Bennett HL
(2013)
Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?
in BJU international
Berry PA
(2011)
The calcium sensor STIM1 is regulated by androgens in prostate stromal cells.
in The Prostate
Bonilla C
(2013)
Using genetic proxies for lifecourse sun exposure to assess the causal relationship of sun exposure with circulating vitamin d and prostate cancer risk.
in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Brooke GN
(2011)
FUS/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth.
in Cancer research
Brown MD
(2010)
Influence of omega-6 PUFA arachidonic acid and bone marrow adipocytes on metastatic spread from prostate cancer.
in British journal of cancer
| Description | Bristol - CRUK Population Research Committee Member |
| Geographic Reach | National |
| Policy Influence Type | Participation in advisory committee |
| Impact | Influence on policy and funding by the CRUK Population Research Committee |
| Description | Bristol - Epidemiology Course |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Cancer Epidemiology 3 day short course |
| Description | Bristol - Member of National Awareness and Early Diagnosis Initiative |
| Geographic Reach | National |
| Policy Influence Type | Participation in advisory committee |
| Impact | Input and influence to this national committee |
| Description | Cambridge - National Prostate Audit |
| Geographic Reach | National |
| Policy Influence Type | Participation in advisory committee |
| Impact | Prof Neal has led a consortium to obtain funding for a prostate cancer audit supported by a number of stakeholders including BAUS, BAUN, BUG and others. This will be substantial funding over the next quinquennium and will directly improve prostate cancer care. |
| Description | Cambridge - Prostate Cancer Advisory Group - Screening Policy Group |
| Geographic Reach | National |
| Policy Influence Type | Participation in advisory committee |
| Impact | Recent editorials from Professor Neal are now being considered by the Screening Policy Group at the Dept of Health. |
| Description | Glasgow - National Prostate Cancer Quality Performance Indicator Development Group Scotland |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Participation in advisory committee |
| Impact | Influence and input to this committee |
| Description | Glasgow - Trustee for Prostate Cancer Charity |
| Geographic Reach | National |
| Policy Influence Type | Participation in advisory committee |
| Impact | Influence to this Charity |
| Description | Newcastle - Member of NCRI Biomarkers and Imaging Group |
| Geographic Reach | National |
| Policy Influence Type | Participation in advisory committee |
| Impact | Influence and input to this committee |
| Description | Newcastle - NCRI Prostate Clinical Studies Group |
| Geographic Reach | National |
| Policy Influence Type | Participation in advisory committee |
| Impact | Influence and input to this committee |
| Description | Newcastle - Prostate Cancer Charity SAC |
| Geographic Reach | National |
| Policy Influence Type | Participation in advisory committee |
| Impact | Influence and input to this committee |
| Description | Oxford - Biomedical Research Centre/Oxford Radcliffe Bio-Repository |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Participation in advisory committee |
| Impact | Invited to join steering committee of Oxford Biomedical Research Centre and Oxford Radcliffe Biorepository |
| Description | Oxford - Deutsch Kerbshilfe |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in advisory committee |
| Impact | Invited to strategy discussions/meetings Deutsch Kerbshilfe, Germany (National Cancer Charity) |
| Description | Oxford - French Ministry |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in advisory committee |
| Impact | External speaker/advisor, French Ministry, Convention on Health Analysis and Management |
| Description | Oxford - Gothenburg University |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in advisory committee |
| Impact | RAE equivalent and external review |
| Description | Oxford - Member of HTA Commissioning Board |
| Geographic Reach | National |
| Policy Influence Type | Participation in advisory committee |
| Impact | Member of HTA Commissioning Board |
| Description | Oxford - NCI USA |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in advisory committee |
| Impact | Invited to advice on biobanking policies |
| Description | York - Association of Medical Research Charities |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Participation in advisory committee |
| Impact | Presented to and shared in the evolution of a policy document from the Association of Medical Research Charities on academic spin out companies and intellectual property. |
| Description | York - Chair - French Prostate Cancer Committee |
| Geographic Reach | Europe |
| Policy Influence Type | Participation in advisory committee |
| Impact | not known |
| Description | York - Kuwaiti and Qatari National Research Programme Advisor |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in advisory committee |
| Impact | not known |
| Description | York - Scientific Chair of the Orchid Trust (LONDON) |
| Geographic Reach | National |
| Policy Influence Type | Participation in advisory committee |
| Impact | not known |
| Description | Bristol - BMA Gunton Award |
| Amount | £34,803 (GBP) |
| Organisation | British Medical Association (BMA) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2010 |
| End | 09/2013 |
| Description | Bristol - CRUK |
| Amount | £189,534 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2012 |
| End | 12/2014 |
| Description | Bristol - NIHR |
| Amount | £4,500,000 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2012 |
| End | 03/2016 |
| Description | Bristol - NIHR |
| Amount | £319,815 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2011 |
| End | 06/2013 |
| Description | Bristol - WCRF |
| Amount | £224,387 (GBP) |
| Organisation | World Cancer Research Fund |
| Sector | Charity/Non Profit |
| Country | Global |
| Start | 04/2012 |
| End | 03/2015 |
| Description | Bristol charity - Above & Beyond |
| Amount | £44,840 (GBP) |
| Organisation | University Hospitals Bristol NHS Foundation Trust |
| Department | Above and Beyond Grants |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2011 |
| End | 09/2012 |
| Description | Cambridge - CANCURE (2m euros across 11 participants) |
| Amount | £188,564 (GBP) |
| Funding ID | 20970 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 07/2006 |
| End | 06/2010 |
| Description | Cambridge - CRUK Programme Grant |
| Amount | £1,439,674 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2010 |
| End | 03/2015 |
| Description | Cambridge - CRUK TRICC |
| Amount | £525,098 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2010 |
| End | 12/2012 |
| Description | Cambridge - Cytosystems |
| Amount | £100,747 (GBP) |
| Organisation | Cytosystems Ltd |
| Sector | Private |
| Country | United Kingdom |
| Start | 04/2009 |
| End | 05/2011 |
| Description | Cambridge - ICGC - next generation sequencing |
| Amount | £500,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2011 |
| End | 12/2013 |
| Description | Cambridge - NIHR Senior Investigator Award |
| Amount | £75,000 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2008 |
| End | 03/2013 |
| Description | Cambridge - National Institute of Health |
| Amount | £48,425 (GBP) |
| Organisation | National Institutes of Health (NIH) |
| Sector | Public |
| Country | United States |
| Start | 07/2010 |
| End | 06/2011 |
| Description | Cambridge - PHILIPS |
| Amount | £207,000 (GBP) |
| Organisation | Koninklijke Philips Electronics N.V. |
| Department | Philips |
| Sector | Private |
| Country | Global |
| Start | 07/2007 |
| End | 12/2012 |
| Description | Cambridge - ProMark |
| Amount | £341,510 (GBP) |
| Funding ID | 202059 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2008 |
| End | 12/2012 |
| Description | Cambridge Cancer Research Fund |
| Amount | £176,237 (GBP) |
| Organisation | University of Cambridge |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 06/2010 |
| End | 05/2013 |
| Description | Cambridge/Bristol/Oxford - CAP |
| Amount | £1,125,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2010 |
| End | 12/2012 |
| Description | Cambridge/Bristol/Oxford - NIHR, HTA, ProtecT |
| Amount | £13,700,000 (GBP) |
| Organisation | National Institute for Health Research |
| Department | Health Technology Assessment Programme (HTA) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2009 |
| End | 12/2013 |
| Description | Newcastle - CRUK |
| Amount | £220,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2012 |
| End | 01/2016 |
| Description | Newcastle - Prostate Cancer Charity |
| Amount | £198,000 (GBP) |
| Organisation | Prostate Cancer UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2010 |
| End | 09/2013 |
| Description | Newcastle - Sanofi Aventis |
| Amount | £175,000 (GBP) |
| Organisation | Sanofi |
| Department | Aventis |
| Sector | Private |
| Country | France |
| Start | |
| Description | Newcastle CRUK/AstraZeneca/CRUK/AstraZeneca jointly |
| Amount | £120,000 (GBP) |
| Organisation | Autistica |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2010 |
| End | 09/2014 |
| Description | Oxford - NIHR Senior Investigator award |
| Amount | £125,000 (GBP) |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Oxford - Pro-nest |
| Amount | £526,925 (GBP) |
| Funding ID | 238278 |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | 01/2010 |
| End | 12/2013 |
| Description | Oxford - Prostate Cancer Charity |
| Amount | £248,975 (GBP) |
| Organisation | Prostate Cancer UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | York - Yorkshire Cancer Research |
| Amount | £2,200,000 (GBP) |
| Organisation | Yorkshire Cancer Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | York - Yorkshire Cancer Research |
| Amount | £210,000 (GBP) |
| Organisation | Yorkshire Cancer Research |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Title | Bristol - GWAS controls |
| Description | 1500 cases and controls nested within ProtecT Study |
| Type Of Material | Database/Collection of Data/Biological Samples |
| Provided To Others? | No |
| Impact | Contribution to papers on GWAS (x2 Nature Genetics; xa JNCI) |
| Title | Bristol - Phenotypes nested within ProtecT Study case control study |
| Description | Database of the following phenotypes nested within the ProtecT study case-control study: components of the IGF system, n=3000 cases and 3000 controls (IGF-I, IGF-II, IGFBP-2, IGFBP-3); vitamins D, A, E, folate, B12, homocystein, n=1500 cases and 1500 controls. |
| Type Of Material | Database/Collection of Data/Biological Samples |
| Provided To Others? | No |
| Impact | Published output on IGFs |
| Title | Cambridge - CANCAP |
| Description | The previously funded CANCAP project jointly between Cooper and Neal is now being analysed and will include CGH array technology and SNP6 results which again when published will be available as a public resource. |
| Type Of Material | Data analysis technique |
| Provided To Others? | No |
| Impact | The previously funded CANCAP project jointly between Cooper and Neal is now being analysed and will include CGH array technology and SNP6 results which again when published will be available as a public resource. |
| Title | Cambridge - Prostate Cancer collections - collaboration with Southern Collaborative |
| Description | Joint database for prostate cancer collections funded under ProMPT is being set up together with the Sountern Collaborative. The database will go live to offer researchers the opportunity to send in bids to access specimens in the excess specimens collected as part of ProMPT |
| Type Of Material | Database/Collection of Data/Biological Samples |
| Provided To Others? | No |
| Impact | New web-based access for tissue just activated |
| Title | Cambridge - high throughput sequencing |
| Description | Several resources put on line from high throughput sequencing for ChIP sequencing (EMBOJ paper Massie et al). High throughput sequencing available for local ProMPT members including data from paraffin embedded material and initial date from next generation sequencing. |
| Type Of Material | Database/Collection of Data/Biological Samples |
| Provided To Others? | No |
| Impact | Several resources put on line from high throughput sequencing for ChIP sequencing (EMBOJ paper Massie et al). High throughput sequencing available for local ProMPT members including data from paraffin embedded material and initial date from next generation sequencing. |
| Title | Glasgow - Docetaxel resistant prostate cancer cells |
| Description | Used among collaborating centres within ProMPT |
| Type Of Material | Cell line |
| Provided To Others? | No |
| Impact | new collaborative projects in train |
| Title | Newcastle - siRNA library screens and assay development for p68 |
| Description | Medium scale siRNA library screens and assay development for HTS Specific Phospho-p68 antibody generated |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | Medium scale siRNA library screens and assay development for HTS Specific Phospho-p68 antibody generated |
| Title | Newcastle - tissue microarray |
| Description | Further expansion of prostate cancer tissue microarray |
| Type Of Material | Data analysis technique |
| Provided To Others? | No |
| Impact | not known |
| Title | Oxford - New Ethics Approval for bone marrow/bone biopsy |
| Description | Ethics approval that has made anew line of enquiry possible. |
| Type Of Material | Improvements to research infrastructure |
| Provided To Others? | No |
| Impact | New ethics approval for collection of bone marrow/bone biopsies prospectively from prostate cancer patients to study bone microenvironment. |
| Title | Oxford - artificial intelligence |
| Description | artificial intelligence (fuzzy logic) |
| Type Of Material | Data analysis technique |
| Provided To Others? | No |
| Impact | Continuing development of artificial intelligence (fuzzy logic) to interpret clinicopathological data to predict disease outcome, and large array data analysis. |
| Title | Oxford - new Surgical Oncology section |
| Description | new research section |
| Type Of Material | Improvements to research infrastructure |
| Provided To Others? | No |
| Impact | Establishment of Surgical Oncology as new section of the CRUK Oxford Cancer Research Centre |
| Title | York - PTT273 |
| Description | Generation of >100 monoclonal antibodies against a prostate cancer stem cell target PTT273. Of these, 3 were selected with the highest PTT273 enzyme inhibiting activity which were able to co-select with the AC133 antibody for CSC's in primary tissue. However, affinity was insufficient to use for in vivo inhibition experiments (this was largely funded and carried out in Pro-Cure Therapeutics as part of our therapeutic development programme) |
| Type Of Material | Antibody |
| Provided To Others? | No |
| Impact | Start up funding for new biotech company |
| Title | York - PTT273 |
| Description | We have 3 highly specific, but relatively low affinity monoclonal antibodies against a prostate cancer stem cell antigen PTT273, and have generated recombinant protein from this antigen for ELISA on human sera, and sufficient (4mg) of human cell derived protein from another potential CSC antigen PTT256 for monoclonal antibody production (Pro-Cure Therapeutics). |
| Type Of Material | Model of mechanisms or symptoms - human |
| Provided To Others? | No |
| Impact | start up funding for new biotech company |
| Title | York - Xenograft |
| Description | We have developed a new and relevant in vivo xenograft model for prostate cancer in immunocompromised mice (Rag2-/-, GammaC -/-). We are able to serially transplant and to freeze tumour cell aliquots from an original tissue fragment, expanding both the tumour initiating cell population, and providing a testing tool (IP filed by Pro-Cure Therapeutics ) for novel therapeutics. In this model true Gleason grade 6 cancer are NOT tumorigenic, mirroring clinical outcome in human patients, where a Gleason grade 7 (or the presence of a pattern 4 is synonymous with bad prognosis). We now have 15 near patient serially transplantable tumours from both hormone sensitive and castration resistant tumours. |
| Type Of Material | Model of mechanisms or symptoms - human |
| Provided To Others? | No |
| Impact | We now have 15 near patient serially transplantable tumours from both hormone sensitive and castration resistant tumours. |
| Title | York - Xenografts |
| Description | 1. A series of primary xenografts from patients with Gleason grade 7+ tumours and castration resistant recurrences, with back up of lymphocyte and primary cell cultures from the same patients. 2. A truly malignant xenograft model of prostate cancer primary tissues. 3. The ability to freeze and regraft fractionated human epithelial cells from xenografts |
| Type Of Material | Model of mechanisms or symptoms - human |
| Provided To Others? | No |
| Impact | Studies underway to carry out expression profiling |
| Title | York - YCSSA bioinformatics tool |
| Description | As part of a collaboration with the York System for Complex System Analysis (YCSSA) we have developed new bioinformatics tools to analyse gene expression datasets, as applied to prostate differentiation. This was funded by a pump-priming grant from YCR. Some of the primary data analysed was generated during and supported in part by the Prompt project. |
| Type Of Material | Data analysis technique |
| Provided To Others? | No |
| Impact | Funding from YCR |
| Title | York - microRNA |
| Description | We have generated (in collaboration with Univ of Tampere) a microRNA expression database from fractionated cell populations from Normal, malignant and castration-resistant prostate cancer. |
| Type Of Material | Database/Collection of Data/Biological Samples |
| Provided To Others? | No |
| Impact | We have generated (in collaboration with Univ of Tampere) a microRNA expression database from fractionated cell populations from Normal, malignant and castration-resistant prostate cancer. |
| Title | York - software tools |
| Description | We have developed new software tools for (i) in silico modelling of prostate epithelial differentiation and cell fate and (ii) Analysis of candidate prostate cancer genes in 'big datasets' , to identify coregulated genes (IP filed here by Univ of York) |
| Type Of Material | Data analysis technique |
| Provided To Others? | No |
| Impact | not known |
| Description | Bristol - Role of Fascin in prostate cancer prevention |
| Organisation | University of Bristol |
| Department | School of Biochemistry Bristol |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Co-supervision of PhD Student |
| Collaborator Contribution | Professor Richard Martin has developed a collaboration with Professor Jo Adams (Dept of Biochemistry, University of Bristol) to investigate the role of fascin in prostate cancer prevention. They are co-supervising a Wellcome Trust funded PhD student to undertake the work. |
| Impact | Ongoing work towards PhD |
| Start Year | 2010 |
| Description | Cambridge - Colin Cooper - Whole Genome Sequencing |
| Organisation | Institute of Cancer Research UK |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Development of idea; careful development of methodologies for tissue processing; will be contributing a major number of cases |
| Collaborator Contribution | Collaboration with Colin Cooper to put in a request to CRUK for funding for whole genome sequencing for prostate cancer. This is likely to lead to a very major award and a major impact on prastate cancer practice. |
| Impact | Grant application due to be announced 1st week in December |
| Start Year | 2010 |
| Description | Cambridge - EC Funding |
| Organisation | deCODE genetics |
| Country | Iceland |
| Sector | Academic/University |
| PI Contribution | Running clinical studies group |
| Collaborator Contribution | collaboration with other EC departments |
| Impact | Grant awarded from EC |
| Start Year | 2008 |
| Description | Cambridge - GSK Novel metabolic inhibitors |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | joint exchange of know how |
| Collaborator Contribution | joint exchange of know how to look at novel metabolic inhibitors involved in prostate cancer. Currently pre-clinical and involving novel imaging technologies. (C11 acetate but likely to move to man in the near future) |
| Impact | To look at novel metabolic inhibitors involved in prostate cancer. Currently pre-clinical and involving novel imaging technologies (C11 acetate but likely to move to man in the near future). |
| Start Year | 2011 |
| Description | Cambridge - ICOGS, PRACTICAL, NIH Consortium |
| Organisation | Institute of Cancer Research UK |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | DNA from our collections formed a significant number of the cases and controls |
| Collaborator Contribution | Request to join in collaborations within Europe, Australia and the US for prostate cancer whole genome sequencing. We are now formally a part of a number of collaborations which are funded including ICOGS, PRACTICAL and a NIH consortium |
| Impact | See publications (x2 Nature Genetics; x1 JNCI plus others) |
| Start Year | 2010 |
| Description | Cambridge - NCI - functional effects of SNPs |
| Organisation | Dana-Farber Cancer Institute |
| Department | Department of Medical Oncology |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Collaboration on laboratory work with Dana Faber |
| Collaborator Contribution | verification of expression data in prostate cancer |
| Impact | Awarded grant from NCI |
| Start Year | 2010 |
| Description | Cambridge / ICR / Marsden - Next Generation Sequencing |
| Organisation | Institute of Cancer Research UK |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Next generation sequencing. This is a proof of principle study which if goes ahead will result in £16.5 million extra funding. |
| Collaborator Contribution | joint exchange of know howjoint exchange of know how |
| Impact | na |
| Start Year | 2011 |
| Description | Cambridge / ICR / Marsden - Next Generation Sequencing |
| Organisation | Royal Marsden NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Next generation sequencing. This is a proof of principle study which if goes ahead will result in £16.5 million extra funding. |
| Collaborator Contribution | joint exchange of know howjoint exchange of know how |
| Impact | na |
| Start Year | 2011 |
| Description | Glasgow - ERK5 |
| Organisation | Institute of Cancer Research UK |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaboration with TAPG on ERK5 expression analysis |
| Impact | not known |
| Start Year | 2010 |
| Description | Newcastle - AstraZeneca |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Developing further collaboration iwht AstraZeneca using novel androgen receptor antagonists they have developed. |
| Impact | not known |
| Start Year | 2010 |
| Description | Newcastle - Biosignatures |
| Organisation | Biosignatures Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | A company with specialist bioinformatics expertise. Defining a protein signature for prostate cancer patients using blood samples and 2D gel electrophoresis. Possible access to stored blood samples from ProtecT/ProMPT. |
| Impact | not known |
| Start Year | 2011 |
| Description | Newcastle - ICL |
| Organisation | Imperial College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaboration with the Bevan Group at ICL - included use of prostae cancer tissue microarray and led to publication of research in Cancer Research |
| Impact | not known |
| Start Year | 2011 |
| Description | Oxford - CARIS epigenetics project |
| Organisation | CARIS Life Sciences |
| Country | United States |
| Sector | Private |
| PI Contribution | Novel project studying methylation in prostate cancer. We are providing a well-annotated bio-repository. |
| Collaborator Contribution | Epigenetics project in prostate cancer |
| Impact | New funded project |
| Start Year | 2010 |
| Description | Oxford - Data Unification |
| Organisation | Institute of Cancer Research UK |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Data Unification for prostate cancer database on ProMPT/ProtecT patients between Northern and Southern Collaboratives |
| Collaborator Contribution | Data Unfiication between ICR, Cambridge and Oxford |
| Impact | New website opened in November |
| Start Year | 2009 |
| Description | Oxford - MSKCC New York |
| Organisation | Memorial Sloan Kettering Cancer Center |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Provision of data from Protect / ProMPT |
| Collaborator Contribution | Collaboration on prostate cancer prediction using PSA |
| Impact | Vickers et al Clin Cancer Res 2010 |
| Start Year | 2010 |
| Description | Oxford / Cambridge / Bristol |
| Organisation | University of Oxford |
| Department | Nuffield Department of Surgical Sciences Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | joint exchange of know how |
| Collaborator Contribution | Submission of an outline application to carry out studies of novel diagnositc pathways including the role of SNPs and gentyping to NIHR |
| Impact | Submission of an outline application to carry out studies of novel diagnositc pathways including the role of SNPs and gentyping to NIHR |
| Start Year | 2011 |
| Description | Oxford/Cambridge - collaboration with Henrik Gronberg Karolinska Institute |
| Organisation | Karolinska Institute |
| Country | Sweden |
| Sector | Academic/University |
| PI Contribution | TMAs received from Karolinska for novel biomarker studies Tissue being sent to Karolinska for expression studies |
| Collaborator Contribution | Joint exchange of know how |
| Impact | New meeting in Oxford in 2011 to take this project forward |
| Start Year | 2010 |
| Description | Oxford/Cambridge/Stockholm |
| Organisation | Karolinska University Hospital |
| Country | Sweden |
| Sector | Hospitals |
| PI Contribution | To look at SNP profiling and new diagnostic pathways in prostate cancer. |
| Collaborator Contribution | To look at SNP profiling and new diagnostic pathways in prostate cancer. Possible application to European Union funding. Joint exchange of know how |
| Impact | New meeting in Cambridge in 2012 |
| Start Year | 2011 |
| Description | York - Toronto : Radiation sensitivity of prostate cancer stem cells |
| Organisation | University of Toronto |
| Department | Department of Medical Biophysics |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Radiation sensitivity of prostate cancer stem cells |
| Impact | not known |
| Start Year | 2010 |
| Title | Cambridge - MSMB assay |
| Description | Recent publication in PLoS One made the front page of the Daily Mail and Daily Telegraph. IP discussions are taking place with a company to discuss the MSMB assay. |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | 2010 |
| Licensed | No |
| Impact | Paper in PLOSOne |
| Title | Cambridge - two novel biomarkers |
| Description | Two new novel biomarkers which will be prognostic are being taken through by Cancer Research Technologies to IP protection |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | 2011 |
| Licensed | Commercial In Confidence |
| Impact | na |
| Title | York - HIP 0072 |
| Description | The patent discloses a genetically engineered baculovirus biotherapy vector that is modified to target the baculovirus to a cell that expresses either gonadotropin receptor or neurotensin receptor (i.e. the prostate). |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | |
| Licensed | No |
| Impact | Facilitation of collaborative reserach with other groups. |
| Title | York - HIP0068 |
| Description | The application discloses the full array data generated from CD133+ prostate cancer stem cells. Claims have been limited to PTT273 as a prostate CSC marker; siRNAs derived from PTT273; vaccines comprising PTT273 and methods to screen for agents that inhibit PTT273. Divisional application strategy in play, to sequentially protect subsequent targets, agents against them and diagnostics for them. |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | |
| Licensed | No |
| Impact | Facilitation of collaborative research with other groups. |
| Title | York - HIP0069 |
| Description | The patent discloses the isolation and characterization of an enriched population of CD133+ cancer stem cells; pure cell cultures of prostate CSCs; animal models containing them; cell based vaccine compositions amongst other claims. |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | |
| Licensed | No |
| Impact | Facilitation of collaborative research with other groups. |
| Title | York - HIP0073 |
| Description | The patent discloses a method for the growth and maintenance of cancerous prostate acini and their use in drug screening |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | |
| Licensed | No |
| Impact | Facilitation of collaborative research with other groups. |
| Title | York - HIP1689 |
| Description | Discloses antagonists of PTT521, specifically nucleic-acid based (e.g. siRNA), which induces cancer stem/progenitor cells to differentiate and stop dividing. The claims are also directed to liposome delivery of siRNA. |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | 2008 |
| Licensed | No |
| Impact | Facilitation of collaborative research with other groups. |
| Title | York - HIP1709 |
| Description | The applications disclose vaccine compositions comprising PTT273 and fragments derived from PTT273 and their use in the treatment of cancer, specifically prostate cancer. |
| IP Reference | US20120100102 |
| Protection | Patent granted |
| Year Protection Granted | 2012 |
| Licensed | Commercial In Confidence |
| Impact | Facilitation of collaborative research with other groups. |
| Title | York - HIP3497 |
| Description | The application relates to a modified baculovirus that targets PTT521 inhibitory RNA (e.g. siRNA, antisense RNA, micro RNA) to prostate cancer cells. |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | |
| Licensed | No |
| Impact | Facilitation of collaborative research with other groups. |
| Title | York - HIP3787 |
| Description | Claims agents that inhibit the expression or activity of PTT522, including methods to treat cancer using the agents. |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | |
| Licensed | No |
| Impact | Facilitation of collaborative research with other groups. |
| Title | York - HIP4039 |
| Description | This application covers non-human mammalian models, and processes to produce them, for the analysis of cancer stem cells and the use of the models in the identification and validation of agents useful in the treatment of cancer. |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | |
| Licensed | No |
| Impact | Facilitation of collaborative research with other groups. |
| Title | York - PCT filing |
| Description | New PCT filing (PCT/GB2011/051913) relating to a group of genes that could serve as markers of prostate cancer and possible targets for therapeutic intervention. |
| IP Reference | WO2012046064 |
| Protection | Patent granted |
| Year Protection Granted | 2012 |
| Licensed | No |
| Impact | see above |
| Title | York - various applications |
| Description | Total of more than 30 worldwide applications in prostate biology and cancer stem cells currently being progressed (mostly transferred to University Spin out company Pro-Cure Therapeutics). Key patents on Prostate 3D modelling have granted in USA, Europe and UK, and Cancer stem cell isolation has granted in UK, Europe awaiting grant in USA, Japan, Australia, Canada. |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | |
| Licensed | Commercial In Confidence |
| Impact | see above |
| Title | ELISA for MSMB |
| Description | Measurement of MSMB to diagnose prostate cancer |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2010 |
| Development Status | Actively seeking support |
| Impact | Paper in PLOS one; continued validation and interaction with several companies |
| Title | York - SiRNA inhibition |
| Description | We have demonstrated the effectiveness of inhibition of a number of potential cancer stem cell targets by SiRNA inhibition in animal models. Again a number of patents to cover this have been filed (by Pro-Cure Therapeutics) |
| Type | Therapeutic Intervention - Cellular and gene therapies |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2011 |
| Development Status | Actively seeking support |
| Impact | We have demonstrated the effectiveness of inhibition of a number of potential cancer stem cell targets by SiRNA inhibition in animal models. Again a number of patents to cover this have been filed (by Pro-Cure Therapeutics) |
| Title | York - monoclonal antibodies target gene PTT273 |
| Description | Initial results were promisiing, but later problem were identified |
| Type | Therapeutic Intervention - Cellular and gene therapies |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2009 |
| Development Status | Closed |
| Impact | Some funding initially by spin-out company |
| Title | York - series of siRNA reagents |
| Description | siRNA against cancer stem cells |
| Type | Therapeutic Intervention - Cellular and gene therapies |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2010 |
| Development Status | Actively seeking support |
| Impact | ongoing develoment |
| Title | York - vaccine |
| Description | We have co-developed a vaccine (still at animal experimental stage) against prostate cancer stem cells with the University of Sheffield. IP has been filed jointly. |
| Type | Therapeutic Intervention - Vaccines |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2011 |
| Development Status | Under active development/distribution |
| Impact | We have co-developed a vaccine (still at animal experimental stage) against prostate cancer stem cells with the University of Sheffield. IP has been filed jointly. |
| Company Name | Newcastle - NEPAF |
| Description | Collaboration with local proteomics company to investigate protein components of the androgen receptor signalling cascade. |
| Year Established | 2010 |
| Impact | Already led to one publication (Gaughan et al 2010) |
| Company Name | Pro-Cure Therapeutics Ltd |
| Description | Pro-Cure therapeutics has spun out of our laboratory. 10 scientists at present. Currently negotiating research agreements with two major pharma companies. |
| Year Established | 2010 |
| Impact | Novel company employing people in York • Pro-Cure Therapeutics, my spin out company has continued trading and employing 12 scientists, through difficult times in 2011. The loss of a multi-million pound contract with a major pharma company through policy changes at the parent company, and after extensive 12 months' due diligence has placed the company in severe financial difficulty, and the shareholders have decided to put it up for sale (August 2011). This process is now well under way. |
| Website | http://www.pro-cure.uk.com/ |
| Description | Cambridge - CRUK Cambridge Research Institute |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Primary Audience | Public/other audiences |
| Results and Impact | Dr Hayley Whitaker regularly presents to non-academic audiences who are interested in the translational research being carried out at the Institute. None |
| Year(s) Of Engagement Activity | 2010 |
| Description | Cambridge - lay audiences and media |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Primary Audience | Public/other audiences |
| Results and Impact | various lay audiences locally and nationally NA |
| Year(s) Of Engagement Activity | 2011 |
| Description | Cambridgeshire Prostate Cancer Support Group |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Primary Audience | Public/other audiences |
| Results and Impact | 200 patients and family members attended a talk on the translational research programmes None |
| Year(s) Of Engagement Activity | 2010 |
| Description | Newcastle - CRUK Fundraising Event |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | Two large organised CRUK Fundraising events that mentioned MRC funded research additional grant funding for the group |
| Year(s) Of Engagement Activity | 2010 |
| Description | Newcastle - Northern Institute for Cancer Research Open Day |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | Presentations to local fundraisers not known |
| Year(s) Of Engagement Activity | 2010 |
| Description | Newcastle - Presentation Rotterdam, Amsterdam, ICR, Washington |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | Presentations at conferences in Rotterdam, Amsterdam, ICR and Washington Not known |
| Year(s) Of Engagement Activity | 2010 |
| Description | Newcastle - Race for Life |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Primary Audience | Public/other audiences |
| Results and Impact | short talks and discussions at Regional Cancer Charity fund raising events - Race for Life (Newcastle and Gateshead) na |
| Year(s) Of Engagement Activity | 2011 |
| Description | York - BBC Local Radio |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Primary Audience | Public/other audiences |
| Results and Impact | Review of the newspapers on the local BBC Radio station giving a scientific point of view and selecting articles of scientific interest to the general public NA |
| Year(s) Of Engagement Activity | 2011 |
| Description | York - Laboratory open evenings |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Primary Audience | Public/other audiences |
| Results and Impact | My group have presented public information lectures at laboratory open evenings. On each evening, 3 graduate students gave short accounts of their thesis research followed by question and answer sessions and a guided tour of the Department with demonstrations of some key (and stimulating) technology. na |
| Year(s) Of Engagement Activity | 2011 |
| Description | York - Local patient support group |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | Presentation of output of our research to a local patient support group at York Hospital, to two local YCR fund raising committees and to the annual meeting of all YCR collection committees. NA |
| Year(s) Of Engagement Activity | 2011 |
| Description | York - Local patient support groups and schools |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Primary Audience | Schools |
| Results and Impact | Regular non-scientific account of research to local patient support groups and local schools None |
| Year(s) Of Engagement Activity | 2010 |
| Description | York - Masonic Lodge |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Primary Audience | Public/other audiences |
| Results and Impact | Dr Davide Pellacani attended a dinner of the local Masonic Lodge who have sponsored some of his research as part of a grant to YCR. NA |
| Year(s) Of Engagement Activity | 2011 |
| Description | York - Presentation to Masonic Grand Charity |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Primary Audience | Public/other audiences |
| Results and Impact | Presented talks at Masonic functions and assisted in preparing an information sheet for Masons on benefits of being screened for prostate cancer Three non-symptomatic tumours from 1000 patients have been detected. |
| Year(s) Of Engagement Activity | 2010 |
| Description | York - Prostate Cancer Charity |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | A formal lecture on new screening methods for prostate cancer to the Prostate Cancer Charity Patients' Forum held at the Central Hall Westminster NA |
| Year(s) Of Engagement Activity | 2011 |
| Description | York - SKY News and Radio 4 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Primary Audience | Public/other audiences |
| Results and Impact | Appearance on SKY News and contribution to the Radio 4 programme Saving the Earth, discussing the use of jellyfish proteins for cancer imaging. NA |
| Year(s) Of Engagement Activity | 2011 |